Substance / Medication

Cyproheptadine hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
BDNF rs6265 (Val66Met) Polymorphism as a Risk Factor for Blepharospasm.
Siokas Vasileios, Kardaras Dimitrios, Aloizou Athina-Maria et al. · Neuromolecular Med · 2019
PMID: 30519954Meta-Analysis
Parkinsonian-Pyramidal syndromes: A systematic review.
Tranchant Christine, Koob Meriam, Anheim Mathieu · Parkinsonism Relat Disord · 2017
PMID: 28256436Meta-Analysis
Sun exposure is an environmental factor for the development of blepharospasm.
Molloy Anna, Williams Laura, Kimmich Okka et al. · J Neurol Neurosurg Psychiatry · 2016
PMID: 25904812Meta-Analysis
Secondary blepharospasm associated with structural lesions of the brain.
Khooshnoodi M A, Factor S A, Jinnah H A · J Neurol Sci · 2013
PMID: 23747003Meta-AnalysisFull text (PMC)
The prevalence of primary dystonia: a systematic review and meta-analysis.
Steeves Thomas D, Day Lundy, Dykeman Jonathan et al. · Mov Disord · 2012
PMID: 23114997Meta-Analysis
Botulinum toxin type A therapy for blepharospasm.
Costa J, Espírito-Santo C, Borges A et al. · Cochrane Database Syst Rev · 2005
PMID: 15674969Meta-Analysis
Cushing's syndrome - Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies.
Ragnarsson Oskar · Best Pract Res Clin Endocrinol Metab · 2020
PMID: 32139169Review
The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer/treatment-related cachexia.
Couluris Marisa, Mayer Jennifer L R, Freyer David R et al. · J Pediatr Hematol Oncol · 2008
PMID: 18989154TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cyproheptadine hydrochloride (substance)
SNOMED CT
15352003
UMLS CUI
C0354872

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.